Hemogenyx Pharmaceuticals annual net debt
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Net Debt Growth & History (HEMO)
Hemogenyx Pharmaceuticals's net debt was £417,816 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £417,816 | −£2.0M | −83.04% |
| 2024 | 2024-12-31 | £2.5M | £765,536 | +45.08% |
| 2023 | 2023-12-31 | £1.7M | £808,208 | +90.80% |
| 2022 | 2022-12-31 | £890,077 | £7.7M | — |
| 2021 | 2021-12-31 | −£6.8M | −£6.6M | — |
| 2020 | 2020-12-31 | −£184,167 | — | — |
Hemogenyx Pharmaceuticals quarterly net debt
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | £417,816 | −£2.0M | −83.04% |
| Q2 2025 | 2025-06-30 | £2.0M | — | — |
| Q4 2024 | 2024-12-31 | £2.5M | — | — |
Hemogenyx Pharmaceuticals net debt trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's net debt increased from −£184,167 to £417,816, a change of £601,983. The latest reported quarter, Q4 2025, shows £417,816.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗